FormFox Competitors

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

Clear and confident health care decisions begin with questions. At Labcorp, we’re constantly in pursuit of answers. As a global leader of innovative and comprehensive laboratory services, we help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. Our more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about Labcorp (NYSE: LH) at www.labcorp.com.

Since December 1992, Smart Start has made an impact in the industry as the world leader of services and technologies that are Separating Drinking From Driving® and Setting the Standard in Alcohol Monitoring Technology®. Throughout the years, we have focused on Ignition Interlocks, building one of the largest, most successful programs in the world. With over a million clients to date and experience working in the U.S. and multiple countries, we provide a unique perspective on operating efficient, effective, service-driven Ignition Interlock and alcohol monitoring device programs. Smart Start is also renowned for its customer service – both to their clients and to the monitoring authorities who order the Interlock Devices and/or alcohol monitoring devices. Our products’ ease of use, our custom-designed software and the convenience of our service make Smart Start the preferred provider for clients. The professionalism, flexibility and responsiveness in addressing the requirements of each state’s monitoring authorities enhance Smart Start’s visibility and influence within the industry. We are the only firm in the industry offering fully integrated Ignition Interlock services, encompassing manufacturing, installation, service, and comprehensive monitoring and reporting.